FIELD: chemistry.SUBSTANCE: invention relates to a compound of formula (I) and/or a pharmaceutically acceptable salt thereof. In formula (I), X is C； Y is O or S； 6 to 5-member condensed ring system A-B is selected from:and ,Q is selected from heteroaryl； R1 is selected from: hydrogen, C1-6 alkyl, heterocyclyl, heterocyclyl-C1-4 alkyl, wherein heterocyclyl is unsubstituted or is substituted with at least one substituent, wherein one, two, three or four substituents are independently selected from R6a； R2 selected from: C3-10 cycloalkyl, wherein the cycloalkyl is unsubstituted or is substituted with at least one substituent independently selected from R6a； R3 and R4 are independently selected from: hydrogen, C1-10 alkyl and C3-10 cycloalkyl； or R3 and R4 together with the nitrogen atoms to which they are attached form a 4 to 6 membered ring containing 0 or 1 heteroatom independently selected from oxygen and nitrogen and optionally substituted with 1 R6a； each R5 independently selected from: C1-10 alkyl, -C(O)R7； each R6a independently selected from: -C1-10 alkyl, -OR8, -NR7R8, -(CR9R10)tOR8, -(CR9R10)tS(O)rR8, -C(O)R7 and -C(O)NR7R8； each R7 and each R8 independently selected from: hydrogen and C1-10 alkyl, wherein alkyl is unsubstituted or substituted with one substituent R6a； or R7 and R8 together with the atom(s) to which they are attached form a heterocyclic ring comprising 6 members, containing 0 or 1 additional heteroatom, independently selected from oxygen and nitrogen, and optionally substituted with 1 R6a； each R9 and each R10 are independently selected from: hydrogen； m is independently selected from 0 and 1； each r is 2； each t is independently selected from 1, 2 and 3； wherein heteroaryl is 6-membered aromatic monocyclic rings containing from 1 to 2 heteroatoms selected from N, the remaining ring atoms being carbon atoms； 9-10 membered bicyclic rings containing from 2 to 3 heteroatoms selected from N, the remaining ring atoms being carbon atoms, and where
